Cytokinetics, Incorporated
NASDAQ:CYTK
Overview | Financials
Company Name | Cytokinetics, Incorporated |
Symbol | CYTK |
Currency | USD |
Price | 46.87 |
Market Cap | 5,531,316,180 |
Dividend Yield | 0% |
52-week-range | 44.49 - 86.63 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Robert I. Blum |
Website | https://www.cytokinetics.com |
An error occurred while fetching data.
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD